..

80%

20%

86 3

ex:DNA

WTO

(Conventional live vaccines)

50

40

30

20

10

0
84

85

86

87

88

89

90

91

92

93

1.

2005

35

 2.

(Conventional inactivated or inacti-

R
(Multivalent vaccines)

(multivalent)

vated vaccines )

(epitopes)

DNA (DNA vaccine )

DNA DNA

b-propiolactone

DNA

DNA

BTT

DNA

(Subunit vaccines )

1.

2. (non-live vaccine)

3. DNA

4. DNA

DNA

DNA

(BEVSbaculovirus express vector system)

DNA

B DNA

DNA

R(synthetic peptide)

R(peptide vaccine)

36

2005

(Toxoids )

2.

(Gene-deleted vaccines )

3. (canarypox)

aroAcyacrp

4.

5. (Semliki Forest virus)

(Marker vaccines )

(Newcastle disease virus)

(BRSVbo-

vine respiratory syncytial virus)

(BVDbovine viral diarrhea)

6.

(IBR; infectiou bovine rhinotracheitis)

fowlpox

Mycoplasma gallisepticum

(Synthetic vaccines)

(Vector vaccines )

RNA

(parvovirus)

1.

(Edible vaccines)

2005

37

15%

20%

25%

40%

rehydrating agents

Animal Biotechnology: Technologies, Companies

and Markets, A Jain PharmaBiotech Report, Nov.
2003

1.

33 160
10

20 2000 7

2004 32

Animal Pharm Report 2009

409.35

2.36 0.22 2.21

27

40

13%
12%

29%
50%

25%

56%
7%

Animal Biotechnology: Technologies, Companies

and Markets, A Jain PharmaBiotech Report, Nov.
2003

38

1%
7%
Animal Pharm Report, Veterinary Vaccines

2005

70

DNAA Jain

31%21.114.9

PharmaBiotech Report2005

2.9

31

(%)
70

2.9

360

14.9

380

15.7

270

11.2

50

2.1

510

21.1

30

1.2

2420

100

Animal Pharm estimates

3,500
3,000
2,500
2,000
1,500
1,000
500
0

31.0

750

1,250
800

720
1,100

2002

1,250

2003

900

1,400

2004

1,850

2005

Animal Biotechnology: Technologies, Companies

and Markets, A Jain PharmaBiotech Report, Nov.
2003

2000

2.

Merial Virbac

2002 4 2005 16

2002

2003

2004

2005

1,350

1,500

1,600

1,790

800

900

1,000

1,250

250

300

410

540

400

740

1,100

1,600

2,800

3,440

4,110

5,180

Animal Biotechnology: Technologies, Companies and Markets, A Jain PharmaBiotech Report, Nov. 2003

2005

39

 2004

Merial

18.02

18.02

100%

Pfizer

525

20.15

4%

Intervet

170

13

8%

Bayer

388

10.2

8%

Wyeth

174

8.3

5%

Virbac

4.62

4.62

100%

Schering-Plough

83

7.7

9%

Boehringer Ingelheim

111.52

4%

(Fort Dodge Animal Health)

SmithKline Beecham Sanofi-Synthelabo

2002 Pfizer 600 Pharmacia

Mallinckrodt Solvay Hoechst Aventis

Pfizer

1995Roche

Hoffman-La Roche

16.25Pfizer

10

Merial Pfizer

2002 9

35

Pharmacia

DSM

Pfizer 1.5 2

1996Ciba-Geigy

Pfizer 2003

Sandoz Novartis

Merial 1997 Rhone Merieux

Merck

1999 11 Intervet

(HRVet) 2000 6

Intervet Intervet

Intervet

40

2005

30

2004 6

R
2005 3

SWOT
(Strength)

(Weakness)

(Opportunity)

(Threat)

12,600

10,000

1,500

2005

41

1,200

600

1. 2004 ITIS
2. 2005 ITIS
3.

4.
5.

84,800

6.
7. Technologies, Companies and Markets Animal Bio-

12,500

technology
8. Veterinary Vaccines Animail Pharm Report

42

2005